Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific’s Apex

This article was originally published in The Gray Sheet

Executive Summary

Percutaneous transluminal coronary angioplasty catheter debuts Nov. 10 following PMA approval. The "high performance" device is designed to treat "the most challenging atherosclerotic lesions," and is available in both Monorail and over-the-wire versions, the firm says. In addition, Apex includes two different 1.5 mm designs: The Apex Push Catheter enhances "pushability" for tight lesions, and the Apex Flex Catheter enhances "trackability" for tortuous arteries, Boston Scientific says. The system also includes balloon diameters from 1.5 mm to 5.0 mm, with lengths from 8 mm to 40 mm. Boston Scientific believes Apex will help the company improve its 65% share of the U.S. balloon catheter market
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT026788

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel